Viridian Therapeutics, Inc. $VRDN Shares Sold by The Manufacturers Life Insurance Company

Posted by Geri Gentry on Aug 11th, 2026

The Manufacturers Life Insurance Company decreased its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 27.7% during the 1st quarter, Holdings Channel reports. The fund owned 81,425 shares of the company’s stock after selling 31,257 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Viridian Therapeutics were worth $1,593,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Commodore Capital LP boosted its holdings in Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter. State Street Corp boosted its holdings in Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock valued at $107,879,000 after purchasing an additional 912,394 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Viridian Therapeutics by 42.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock worth $107,036,000 after purchasing an additional 1,021,310 shares during the period. Finally, Perceptive Advisors LLC increased its position in Viridian Therapeutics by 108.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after purchasing an additional 1,580,303 shares during the period.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $23.06 on Tuesday. The firm has a market capitalization of $2.61 billion, a PE ratio of -6.84 and a beta of 0.91. Viridian Therapeutics, Inc. has a 52 week low of $13.18 and a 52 week high of $34.29. The firm’s 50-day simple moving average is $18.51 and its 200 day simple moving average is $21.52. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. On average, equities research analysts predict that Viridian Therapeutics, Inc. will post -4.02 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on VRDN shares. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Wells Fargo & Company raised Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $31.00 in a report on Monday, June 29th. Royal Bank Of Canada increased their price objective on Viridian Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday. Stifel Nicolaus set a $39.00 target price on Viridian Therapeutics in a report on Wednesday, May 13th. Finally, Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.93.

View Our Latest Report on VRDN

Viridian Therapeutics Company Profile

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.